---
input_text: "Antioxidant supplementation for sickle cell disease. BACKGROUND: Sickle
  cell disease (SCD) refers to a group of genetic disorders characterized by the presence
  of an abnormal haemoglobin molecule called haemoglobin S (HbS). When subjected to
  oxidative stress from low oxygen concentrations, HbS molecules form rigid polymers,
  giving the red cell the typical sickle shape. Antioxidants have been shown to reduce
  oxidative stress and improve outcomes in other diseases associated with oxidative
  stress. Therefore, it is important to review and synthesize the available evidence
  on the effect of antioxidants on the clinical outcomes of people with SCD. OBJECTIVES:
  To assess the effectiveness and safety of antioxidant supplementation for improving
  health outcomes in people with SCD. SEARCH METHODS: We used standard, extensive
  Cochrane search methods. The latest search date was 15 August 2023. SELECTION CRITERIA:
  We included randomized and quasi-randomized controlled trials comparing antioxidant
  supplementation to placebo, other antioxidants, or different doses of antioxidants,
  in people with SCD. DATA COLLECTION AND ANALYSIS: Two authors independently extracted
  data, assessed the risk of bias and certainty of the evidence, and reported according
  to Cochrane methodological procedures. MAIN RESULTS: The review included 1609 participants
  in 26 studies, with 17 comparisons. We rated 13 studies as having a high risk of
  bias overall, and 13 studies as having an unclear risk of bias overall due to study
  limitations. We used GRADE to rate the certainty of evidence. Only eight studies
  reported on our important outcomes at six months. Vitamin C (1400 mg) plus vitamin
  E (800 mg) versus placebo Based on evidence from one study in 83 participants, vitamin
  C (1400 mg) plus vitamin E (800 mg) may not be better than placebo at reducing the
  frequency of crisis (risk ratio (RR) 1.18, 95% confidence interval (CI) 0.64 to
  2.18), the severity of pain (RR 1.33, 95% CI 0.40 to 4.37), or adverse effects (AE),
  of which the most common were headache, nausea, fatigue, diarrhoea, and epigastric
  pain (RR 0.56, 95% CI 0.31 to 1.00). Vitamin C plus vitamin E may increase the risk
  of SCD-related complications (acute chest syndrome: RR 2.66, 95% CI 0.77 to 9.13;
  1 study, 83 participants), and increase haemoglobin level (median (interquartile
  range) 90 (81 to 96) g/L versus 93.5 (84 to 105) g/L) (1 study, 83 participants)
  compared to placebo. However, the evidence for all the above effects is very uncertain.
  The study did not report on quality of life (QoL) of participants and their caregivers,
  nor on frequency of hospitalization. Zinc versus placebo Zinc may not be better
  than placebo at reducing the frequency of crisis at six months (rate ratio 0.62,
  95% CI 0.17 to 2.29; 1 study, 36 participants; low-certainty evidence). We are uncertain
  whether zinc is better than placebo at improving sickle cell-related complications
  (complete healing of leg ulcers at six months: RR 2.00, 95% CI 0.60 to 6.72; 1 study,
  34 participants; very low-certainty evidence). Zinc may be better than placebo at
  increasing haemoglobin level (g/dL) (MD 1.26, 95% CI 0.44 to 1.26; 1 study, 36 participants;
  low-certainty evidence). The study did not report on severity of pain, QoL, AE,
  and frequency of hospitalization. N-acetylcysteine versus placebo N-acetylcysteine
  (NAC) 1200 mg may not be better than placebo at reducing the frequency of crisis
  in SCD, reported as pain days (rate ratio 0.99 days, 95% CI 0.53 to 1.84; 1 study,
  96 participants; low-certainty evidence). Low-certainty evidence from one study
  (96 participants) suggests NAC (1200 mg) may not be better than placebo at reducing
  the severity of pain (MD 0.17, 95% CI -0.53 to 0.87). Compared to placebo, NAC (1200
  mg) may not be better at improving physical QoL (MD -1.80, 95% CI -5.01 to 1.41)
  and mental QoL (MD 2.00, 95% CI -1.45 to 5.45; very low-certainty evidence), reducing
  the risk of adverse effects (gastrointestinal complaints, pruritus, or rash) (RR
  0.92, 95% CI 0.75 to 1.14; low-certainty evidence), reducing the frequency of hospitalizations
  (rate ratio 0.98, 95% CI 0.41 to 2.38; low-certainty evidence), and sickle cell-related
  complications (RR 5.00, 95% CI 0.25 to 101.48; very low-certainty evidence), or
  increasing haemoglobin level (MD -0.18 g/dL, 95% CI -0.40 to 0.04; low-certainty
  evidence). L-arginine versus placebo L-arginine may not be better than placebo at
  reducing the frequency of crisis (monthly pain) (RR 0.71, 95% CI 0.26 to 1.95; 1
  study, 50 participants; low-certainty evidence). However, L-arginine may be better
  than placebo at reducing the severity of pain (MD -1.41, 95% CI -1.65 to -1.18;
  2 studies, 125 participants; low-certainty evidence). One participant allocated
  to L-arginine developed hives during infusion of L-arginine, another experienced
  acute clinical deterioration, and a participant in the placebo group had clinically
  relevant increases in liver function enzymes. The evidence is very uncertain whether
  L-arginine is better at reducing the mean number of days in hospital compared to
  placebo (MD -0.85 days, 95% CI -1.87 to 0.17; 2 studies, 125 participants; very
  low-certainty evidence). Also, L-arginine may not be better than placebo at increasing
  haemoglobin level (MD 0.4 g/dL, 95% CI -0.50 to 1.3; 2 studies, 106 participants;
  low-certainty evidence). No study in this comparison reported on QoL and sickle
  cell-related complications. Omega-3 versus placebo Very low-certainty evidence shows
  no evidence of a difference in the risk of adverse effects of omega-3 compared to
  placebo (RR 1.05, 95% CI 0.74 to 1.48; 1 study, 67 participants). Very low-certainty
  evidence suggests that omega-3 may not be better than placebo at increasing haemoglobin
  level (MD 0.36 g/L, 95% CI -0.21 to 0.93; 1 study, 67 participants). The study did
  not report on frequency of crisis, severity of pain, QoL, frequency of hospitalization,
  and sickle cell-related complications. AUTHORS' CONCLUSIONS: There was inconsistent
  evidence on all outcomes to draw conclusions on the beneficial and harmful effects
  of antioxidants. However, L-arginine may be better than placebo at reducing the
  severity of pain at six months, and zinc may be better than placebo at increasing
  haemoglobin level. We are uncertain whether other antioxidants are beneficial for
  SCD. Larger studies conducted on each comparison would reduce the current uncertainties."
raw_completion_output: |-
  primary_disease: Sickle cell disease
  medical_actions: Antioxidant supplementation; Vitamin C (1400 mg) plus vitamin E (800 mg) versus placebo; Zinc versus placebo; N-acetylcysteine (1200 mg) versus placebo; L-arginine versus placebo; Omega-3 versus placebo
  symptoms: Frequency of crisis; Severity of pain; Adverse effects; Sickle cell-related complications; Haemoglobin level
  chemicals: Vitamin C; Vitamin E; Zinc; N-acetylcysteine; L-arginine; Omega-3
  action_annotation_relationships: Antioxidant supplementation TREATS oxidative stress IN Sickle cell disease; Vitamin C (with Vitamin E) MAY INCREASE Sickle cell-related complications IN Sickle cell disease; Vitamin C (with Vitamin E) MAY INCREASE Haemoglobin level IN Sickle cell disease; Zinc MAY INCREASE Haemoglobin level IN Sickle cell disease; N-acetylcysteine (1200 mg) MAY NOT INCREASE Haemoglobin level IN Sickle cell disease; L-arginine MAY REDUCE Severity of pain IN Sickle cell disease; L-arginine MAY NOT BE BETTER THAN Placebo IN Sickle cell disease; Omega-3 MAY NOT INCREASE Haemoglobin level IN Sickle cell disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Omega-3 MAY NOT INCREASE Haemoglobin level IN Sickle cell disease

  ===

extracted_object:
  primary_disease: MONDO:0011382
  medical_actions:
    - Antioxidant supplementation
    - Vitamin C (1400 mg) plus vitamin E (800 mg) versus placebo
    - Zinc versus placebo
    - N-acetylcysteine (1200 mg) versus placebo
    - L-arginine versus placebo
    - Omega-3 versus placebo
  symptoms:
    - Frequency of crisis
    - Severity of pain
    - Adverse effects
    - Sickle cell-related complications
    - Haemoglobin level
  chemicals:
    - CHEBI:176783
    - CHEBI:33234
    - CHEBI:27363
    - CHEBI:28939
    - CHEBI:16467
    - Omega-3
  action_annotation_relationships:
    - subject: Antioxidant supplementation
      predicate: TREATS
      object: HP:0025464
      qualifier: MONDO:0011382
      subject_extension: antioxidant supplementation
    - subject: <N/A>
      predicate: <MAY INCREASE>
      object: <Sickle cell-related complications>
      qualifier: <Sickle cell disease>
      subject_qualifier: <N/A>
      object_qualifier: <N/A>
      subject_extension: <Vitamin C (with Vitamin E)>
      object_extension: <N/A>
    - subject: <Vitamin C (with Vitamin E)>
      predicate: <MAY INCREASE>
      object: <Haemoglobin level>
      qualifier: <Sickle cell disease>
      subject_extension: <Vitamin C>
    - subject: Zinc
      predicate: MAY INCREASE
      object: Haemoglobin level
      qualifier: MONDO:0011382
    - predicate: MAY NOT INCREASE
      object: Haemoglobin level
      qualifier: MONDO:0011382
      subject_qualifier: 1200 mg
      subject_extension: CHEBI:28939
    - subject: MAY REDUCE
      predicate: TREATS
      object: Severity of pain
      qualifier: MONDO:0011382
      subject_extension: CHEBI:16467
    - predicate: MAY NOT BE BETTER THAN
      qualifier: MONDO:0011382
      subject_extension: CHEBI:16467
      object_extension: Placebo
    - predicate: MAY NOT INCREASE
      object: Haemoglobin level
      qualifier: MONDO:0011382
      subject_extension: Omega-3
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:81579
    label: erythropoietin
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:33281
    label: antibiotics
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0000756
    label: Blood transfusion
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: HP:0001297
    label: Stroke
  - id: HP:0002863
    label: Myelodysplastic syndrome
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:82594
    label: Ferritin
  - id: MONDO:0000984
    label: thalassemia
  - id: MONDO:0018881
    label: myelodysplastic syndrome
  - id: HP:0002140
    label: Ischemic Stroke
  - id: MONDO:0005380
    label: avascular necrosis
  - id: MAXO:0009047
    label: total hip replacement
  - id: HP:0010885
    label: avascular necrosis
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:9168
    label: sirolimus
  - id: CHEBI:8764
    label: mycophenolate mofetil
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000515
    label: Extracorporeal life support
  - id: HP:0001708
    label: Right ventricular failure
  - id: HP:0033515
    label: opioid dependence
  - id: MONDO:0005632
    label: Acute chest syndrome in sickle cell disease
  - id: HP:0001945
    label: fever
  - id: HP:0001878
    label: Hemolytic anemia
  - id: CHEBI:6121
    label: ketamine
  - id: CHEBI:17303
    label: morphine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0031274
    label: hypovolemic shock
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:18211
    label: citrulline
  - id: CHEBI:3638
    label: chloroquine
  - id: CHEBI:50733
    label: nutritional supplements
  - id: MONDO:0005570
    label: Blood disorders
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0100626
    label: end-stage liver disease
  - id: MONDO:0016363
    label: Iron overload diseases
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0010203
    label: echocardiography
  - id: HP:0002870
    label: obstructive sleep apnoea (OSA)
  - id: HP:0000520
    label: Proptosis
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000058
    label: pharmacological treatment
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: HP:0002878
    label: Acute respiratory failure
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitor
  - id: MAXO:0000652
    label: angiotensin-converting enzyme inhibitor therapy
  - id: HP:0000112
    label: kidney disease
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0000827
    label: serum ferritin measurement
  - id: HP:0001875
    label: neutropenia
  - id: CHEBI:4356
    label: <desferrioxamine (DFO)
  - id: CHEBI:17941
    label: deferiprone (DFP)
  - id: CHEBI:49005
    label: deferasirox (DFX)
  - id: CHEBI:38157
    label: iron chelators
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:9144
    label: silymarin
  - id: MAXO:0000750
    label: conditioning regimens (fludarabine-thiotepa-treosulfan, busulfan-cyclophosphamide)
  - id: CHEBI:82557
    label: treosulfan
  - id: HP:0100602
    label: preeclampsia
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: CHEBI:50858
    label: corticosteroids
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0100639
    label: erectile dysfunction
  - id: CHEBI:71940
    label: Tadalafil
  - id: CHEBI:71942
    label: PDE5 inhibitors
  - id: MONDO:0019740
    label: Acquired thrombotic thrombocytopenic purpura (aTTP)
  - id: CHEBI:24261
    label: Glucocorticoids
  - id: MAXO:0000194
    label: Opioid therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002315
    label: Headache
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: HP:0000832
    label: Primary hypothyroidism
  - id: HP:0011787
    label: Central hypothyroidism
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:30660
    label: Thyroxine
  - id: HP:0001342
    label: Hemorrhagic strokes
  - id: HP:0002326
    label: Transient ischemic attack
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome
  - id: HP:0001923
    label: hemolysis (reticulocytosis)
  - id: MONDO:0800385
    label: Iron overload
  - id: CHEBI:6456
    label: Lidocaine
  - id: CHEBI:75008
    label: <visual analog pain scale (VAS)>
  - id: CHEBI:41264
    label: busulfan (Bu)
  - id: HP:0025322
    label: Venous occlusive disease (VOD)
  - id: MONDO:0005399
    label: Venous thromboembolism (VTE)
  - id: HP:0002094
    label: dyspnea
  - id: MONDO:0007885
    label: Osteonecrosis of the Femoral Head (AVNFH)
  - id: HP:0000969
    label: Oedema
  - id: HP:0006554
    label: Acute Liver Failure
  - id: HP:0002098
    label: Respiratory distress
  - id: MAXO:0001175
    label: liver transplantation
  - id: MAXO:0010033
    label: umbilical cord blood transplantation
  - id: MAXO:0000068
    label: transplantation
  - id: CHEBI:17334
    label: penicillin
  - id: MAXO:0000066
    label: oxygen supplementation
  - id: HP:0002202
    label: pleural effusions
  - id: CHEBI:25805
    label: oxygen
  - id: HP:0002791
    label: alveolar hypoventilation
  - id: HP:0001395
    label: Liver fibrosis
  - id: MAXO:0035078
    label: Pulmonary function testing
  - id: HP:0001944
    label: dehydration
  - id: HP:0011105
    label: fluid overload
  - id: CHEBI:25107
    label: Magnesium
  - id: CHEBI:32599
    label: Magnesium sulphate
  - id: HP:0008209
    label: Premature ovarian insufficiency (POI)
  - id: HP:0011675
    label: Arrhythmias
  - id: HP:0012418
    label: Hypoxia
  - id: MAXO:0000118
    label: immunizations
  - id: MONDO:0100470
    label: Asthma
  - id: HP:0001627
    label: Cardiac abnormalities
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:16480
    label: nitric oxide
  - id: CHEBI:63533
    label: GnRH agonist
  - id: MAXO:0010314
    label: lung computed tomography
  - id: MAXO:0001490
    label: platelet transfusions
  - id: MAXO:0009003
    label: preimplantation genetic testing
  - id: MONDO:0011549
    label: Hyperhemolytic syndrome (HHS)
  - id: HP:0001896
    label: Reticulocytopenia
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: HP:0001900
    label: Increased hemoglobin
  - id: CHEBI:35143
    label: Hemoglobin (Hb)
  - id: HP:0000739
    label: anxiety
  - id: HP:0100806
    label: Sepsis
  - id: MONDO:0018585
    label: Pediatric Arterial Ischemic Stroke
  - id: HP:0003270
    label: abdominal distension
  - id: HP:0002014
    label: diarrhoea
  - id: HP:0002573
    label: rectal bleeding
  - id: CHEBI:50249
    label: anticoagulant
  - id: CHEBI:5855
    label: Ibuprofen
  - id: MONDO:0000001
    label: disease
  - id: CHEBI:32026
    label: Poloxamer 188
  - id: MONDO:0004745
    label: Priapism
  - id: MAXO:0000527
    label: Physical examination
  - id: CHEBI:44915
    label: Propofol
  - id: CHEBI:28304
    label: Heparin
  - id: CHEBI:9449
    label: Terbutaline
  - id: HP:0004749
    label: atrial flutter
  - id: MAXO:0000503
    label: mechanical ventilation
  - id: MAXO:0000600
    label: renal replacement therapy
  - id: MONDO:0005098
    label: Stroke
  - id: MAXO:0000955
    label: noninvasive, bi-level positive airway pressure ventilation (BiPAP)
  - id: HP:0012592
    label: Albuminuria
  - id: HP:0001649
    label: Elevated heart rate
  - id: CHEBI:8455
    label: proguanil
  - id: MAXO:0001075
    label: Circumcision
  - id: HP:0100543
    label: cognitive dysfunction
  - id: HP:0001139
    label: High transcranial Doppler (TCD) velocities
  - id: HP:0000572
    label: Visual loss
  - id: HP:0007902
    label: Vitreous haemorrhage
  - id: HP:0011958
    label: Retinal tear
  - id: HP:0000541
    label: Retinal detachment
  - id: HP:0011506
    label: Choroidal neovascularization
  - id: MONDO:0019542
    label: Acute Liver Failure
  - id: HP:0001399
    label: hepatic failure
  - id: HP:0025085
    label: Bloody stools
  - id: MAXO:0000855
    label: hemoglobin fractionation
  - id: CHEBI:15956
    label: biotin
  - id: HP:0000822
    label: Hypertension
  - id: MAXO:0009012
    label: intrauterine transfusions
  - id: HP:0001941
    label: acidosis
  - id: MONDO:0006978
    label: Splenic Infarct
  - id: HP:0012223
    label: Splenic rupture
  - id: HP:0034336
    label: Splenic Infarct
  - id: HP:0100749
    label: chest pain
  - id: HP:0004870
    label: Chronic hemolytic anemia
  - id: MAXO:0010026
    label: zinc supplementation
  - id: MAXO:0000423
    label: skin biopsy
  - id: HP:0000988
    label: skin rash
  - id: CHEBI:27363
    label: zinc
  - id: HP:0040319
    label: Dark urine
  - id: CHEBI:50131
    label: decitabine
  - id: CHEBI:29548
    label: cytidine deaminase (CDA)
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:145536
    label: Motixafortide
  - id: HP:0006775
    label: Multiple Myeloma
  - id: HP:0003281
    label: increased serum ferritin levels
  - id: HP:0003259
    label: increased serum creatinine
  - id: CHEBI:68478
    label: Everolimus
  - id: CHEBI:63597
    label: leuprolide acetate
  - id: HP:0000789
    label: infertility
  - id: HP:0002092
    label: pulmonary hypertension
  - id: CHEBI:51451
    label: endothelin receptor antagonists
  - id: CHEBI:24526
    label: Haptoglobin (Hp)
  - id: CHEBI:16042
    label: Hemopexin (Hx)
  - id: CHEBI:30413
    label: Heme
  - id: CHEBI:176783
    label: Vitamin C
  - id: CHEBI:33234
    label: Vitamin E
  - id: CHEBI:28939
    label: N-acetylcysteine
  - id: CHEBI:16467
    label: L-arginine
  - id: HP:0025464
    label: oxidative stress
